Buffalo Round Table - November 2, 2019 image

Buffalo Round Table - November 2, 2019

Nov 02, 2019
09:00AM - 03:00PM EDT In the city timezone
Hyatt Place Niagara Falls
310 Rainbow Blvd, Niagara Falls, NY 14303, USA
Overview

On November 2, 2019, a Myeloma Crowd Round Table meeting was held in Buffalo, New York at the Hyatt Place Niagara Falls featuring four myeloma experts, including:

    • Dr. Matthew Drake, Mayo Clinic, Rochester, MN
    • Dr. Jens Hillengass, Roswell Park Comprehensive Cancer Center, Buffalo, NY
    • Dr. Philip McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, NY
    • Dr. Saad Usmani, Levine Cancer Institute, Charlotte, NC

 

Thanks to our Platinum Sponsor

Thanks to our additional Myeloma Crowd Round Table Sponsors: Takeda Oncology, GSK, Celgene, Karyopharm and Adaptive Biotechnologies

 

Highlights
Speakers & Moderators
Healthtree contact Jens Hillengass, MD

Jens Hillengass, MD

Jens Hillengass, MD, PhD, is Professor of Oncology and Chief of the Myeloma and Amyloidosis Service at Roswell Park Cancer Institute in Buffalo, NY.

Jens Hillengass, MD, PhD, is Professor of Oncology and Chief of the Myeloma and Amyloidosis Service at Roswell Park Cancer Institute in Buffalo, NY. Prior to joining Roswell, he was the deputy of the section multiple myeloma of the University Hospital of Heidelberg, Germany, the leader of its autologous stem cell transplantation program, and head of the hemato-oncological imaging research group at the German Cancer Research Center (DKFZ). He completed his medical degree at Heidelberg University, where he later completed residency and fellowship in the department of hematology, oncology, and rheumatology. Dr Hillengass received a Gerok scholarship to study radiology at the German Cancer Research Center. Additionally, he completed a research fellowship at the National Cancer Institute. Dr. Hillengass is member of the Black Swan Research Initiative of the International Myeloma Foundation and the International Myeloma Working Group where he co-chairs the bone and imaging group.
Healthtree contact Philip McCarthy MD

Philip McCarthy MD

My research interests are devoted to developing novel intensive and reduced intensity allogeneic and autologous hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity. I have over 20 years of experience treating HSCT patients and directing clinical and translational HSCT research studies. I have served as chair, or co-chair, of several clinical trials, including CALGB 100104, a phase III clinical trial evaluating lenalidomide maintenance after autologous HSCT for multiple myeloma (MM). This study demonstrated an improved progression-free and overall survival for MM patients receiving lenalidomide maintenance therapy after autologous HSCT. Our team has developed a systematic approach to the evaluation and treatment of HSCT patients with a specific focus on predicting and minimizing treatment-related mortality (TRM). We participate with a core group of basic science and clinical researchers who are committed to the investigation of the complications of autologous and allogeneic HSCT and to the developing novel approaches to improve outcomes.